Molecular Partners AG
NASDAQ:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
NASDAQ:MOLN
Watchlist
Price: 5.08 USD -2.68% Market Closed
Market Cap: 168.6m USD
Have any thoughts about
Molecular Partners AG?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-0.2
Current
-0.1
Median
4.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-0.2
=
Enterprise Value
14.6m CHF
/
EBITDA
-73m CHF
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
CH
Molecular Partners AG
NASDAQ:MOLN
Average EV/EBITDA: 16.2
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 544.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.6 N/A N/A
AU
CSL Ltd
ASX:CSL
19.6
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -110 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-0.3
2-Years Forward
EV/EBITDA
-0.3
3-Years Forward
EV/EBITDA
-0.4

See Also

Discover More